T-DXd Price Negotiations Fail in Parts of UK Free

For the third time, England’s National Institute for Health and Care Excellence (NICE) failed to agree on a price for trastuzumab deruxtecan (T-DXd; Enhertu) with AstraZeneca and Daiichi Sankyo, keeping the companies’ antibody–drug conjugate out of reach for women in England, Wales, and Northern Ireland with HER2-low metastatic breast cancer. Accordingly, NICE guidance continues to say that T-DXd is not a cost-effective therapy for the National Health Services to cover, the first breast cancer treatment NICE has been unable to recommend in 6 years. T-DXd received FDA approval for HER2-low metastatic breast cancer treated with a prior systemic therapy in August 2022; it’s approved for this indication in more than 55 countries.